The european medicines agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressivenon-hodgkin's B-celllymphomas:Summaryofthescientific assessmentof the committee for medicinal products for human use

Oncologist

Volumn 18, Issue 5, 2013, Pages 625-633

  Péan, Elias ^a   Flores, Beatriz ^b   Hudson, Ian ^b   SjöBerg, Jan ^c   Dunder, Kristina ^c   Salmonson, Tomas ^c   Gisselbrecht, Christian ^d   Laane, Edward ^e   Pignatti, Francesco ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d SAINT LOUIS HOSPITAL   (France)

^e North Estonia Regional Hospital   (Estonia)

Author keywords

Aggressive non hodgkin's lymphoma; Ema; European medicines agency; Pixantrone; Pixuvri

Indexed keywords

ANTHRACYCLINE; BREAST CANCER RESISTANCE PROTEIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C8; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOXANTRONE; NAVELBINE; OCTAMER TRANSCRIPTION FACTOR 1; OXALIPLATIN; PIXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BODY WEIGHT; BONE MARROW SUPPRESSION; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEART EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; HYPOTENSION; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHADENOPATHY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; RHINORRHEA; RISK FACTOR; RISK MANAGEMENT; SIDE EFFECT; SKIN DISCOLORATION; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VASCULAR DISEASE; VOMITING;

AGGRESSIVE NON-HODGKIN'S LYMPHOMA; EMA; EUROPEAN MEDICINES AGENCY; PIXANTRONE; PIXUVRI;

ADULT; ANTHRACYCLINES; DRUG APPROVAL; EUROPEAN UNION; FEMALE; HUMANS; ISOQUINOLINES; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; META-ANALYSIS AS TOPIC; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84878201628     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0020     Document Type: Article

References (10)

1. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
2. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-likechemotherapyaloneinyoungpatientswith good-prognosis diffuse large-B-cell lymphoma: A randomized controlled trial by the MabThera International Trial(MInT)Group. LancetOncol 2006;7:379-391.
3. Hazlehurst LA, Krapcho AP, Hacker MP. Correlation of DNAreactivityandcytotoxicity of anewclass of anticancer agents: Aza-anthracenediones. Cancer Lett 1995;91:115-124.
4. Cavalletti E, Crippa L, Mainardi P et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 2007;25:187-195.
5. Dawson LK, Jodrell DI, Bowman A et al. Aclinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer 2000;36:2353-2359.
6. Faivre S, Raymond E, Boige V et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res 2001;7:43-50.
7. Borchmann P, Schnell R, Knippertz R et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001;12:661-667.
8. Borchmann P, Morschhauser F, Parry A et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica 2003;88:888-894.
9. Pettengell R, Coiffier B, Narayanan G et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: A phase 3, multicentre, open-label, randomized trial. Lancet Oncol 2012;13:696-706.
10. European Medicines Agency. European Public Assessment Report for Pixuvri (pixantrone dimaleate). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002055/human_med_001549.jsp. Accessed March 16, 2013.